# Andrographis and Mutant p53 This page covers the experimental **mutant p53 clean-up pulse** idea for **stable mutant p53** states. The logic is specific: * some TP53 mutations create a **harmful full-length mutant protein** * andrographolide has preclinical evidence for helping cells tag some mutant p53 for degradation through **Hsp70** and the **proteasome** * the idea is a **short pulse**, not continuous daily use This is not established clinical practice. {% hint style="warning" %} This is an educational thought experiment only. It is not proven to improve survival or prevent relapse, and it should not be treated as a substitute for oncology care. {% endhint %} ### The basic idea Inside healthy cells, **p53** acts like a safety officer. It helps repair DNA damage or tells badly damaged cells to die. In many cancers, TP53 is mutated. Some mutations do more than remove p53 protection. They create a **stable mutant protein** that can help cancer cells survive, spread, or resist treatment. Andrographolide, a compound from *Andrographis paniculata*, has preclinical evidence for increasing **Hsp70**-mediated binding to some mutant p53 proteins and promoting their degradation through the proteasome. In plain language: * mutant p53 can sometimes behave like a harmful protein load inside cancer cells * andrographolide may help the cell tag some of that protein for disposal * the goal of the idea is **clean-up**, not long-term daily suppression There are **no human trials** showing that an andrographis pulse improves survival or prevents relapse in TP53-mutant cancer. ### The mutation-class split matters This idea makes the most biological sense when the tumour has a **stable gain-of-function missense mutant**, such as: * `R175H` * `R248Q` * `R248W` * `R273H` In those settings, the problem is not only missing p53 activity. The cancer may also be accumulating a harmful full-length mutant protein. That is different from a **frameshift**, **nonsense**, or many **splice-site** mutations, especially when the normal copy is also lost. In those settings, there may be little useful p53 left at all. The problem is then more that the guardian is missing than that a harmful full-length mutant protein is piling up. That means a mutant-protein clean-up strategy is much less relevant by itself. Those tumours are usually thought about through other stress and death pathways rather than through a p53 clean-up idea. ### What a pulse means A pulse means a **short planned block** of andrographis, then a break. The source idea here is not continuous long-term use. It is a limited degradation-focused window. An example **discussion point for clinicians**, not a prescription, would be: * use a standardised andrographis extract for **3-4 days** * aim for roughly **100-180 mg andrographolide per day** * split the daily total into **2-3 doses** * then stop for at least the rest of the **2-week period** * do not repeat more often than the next **fortnight** unless a qualified clinician specifically wants that This ballpark comes from short-term human andrographis use outside oncology. It is **not** cancer-outcome evidence. ### Why is the pulse framed this way The point is not to keep pushing indefinitely. The point is to create a short window in which cells may be more able to: * increase **Hsp70** activity * tag mutant p53 * feed it into the **proteasome** * then stop and allow a rest period This is why the concept is a pulse rather than a permanent protocol. ### Why Hsp70 and the proteasome matter The proteasome is the cell's protein-disposal system. You can think of it as a cellular shredder for unwanted proteins. In the key mutant-p53 study, andrographolide increased **Hsp70** and increased Hsp70 binding to mutant p53. That appears to help deliver mutant p53 toward proteasomal degradation. When the proteasome was blocked with **MG132**, the effect was lost. That supports the idea that the normal proteasome system is required for this clean-up effect. So the logic is not that andrographolide physically drags p53 to the shredder. It appears to change internal stress-response and chaperone signalling so the cell is more likely to tag and clear the mutant protein. ### What may be worth avoiding or reviewing on pulse days Because the concept depends on **proteasome activity**, **Hsp70 signalling**, and some degree of intracellular stress signalling, caution is warranted with anything that may blunt those effects. That includes reviewing: * **prescription proteasome inhibitors** such as bortezomib, carfilzomib, or ixazomib * **high-dose polyphenol supplements** with proteasome-inhibitory or Hsp70-dampening effects in lab systems * **large antioxidant megastacks** that may overly blunt stress signals involved in protein turnover The polyphenol caution is mainly about supplement-level exposure, not normal food intake. Examples often discussed in the lab literature include: * **EGCG** * **quercetin** * **curcumin** * **genistein** * **apigenin** * **luteolin** * **chrysin** * **tannic acid** * **diosmin** * **hesperidin** * **celastrol** * **triptolide** That does **not** mean all of these are automatically harmful in real-world use. It means that during a short degradation-focused pulse, it makes sense to avoid self-designed high-dose stacks unless a knowledgeable clinician wants them there. The same logic applies to very large antioxidant combinations. For example, a heavy stack such as high-dose **NAC**, high-dose **vitamin C**, plus multiple strong polyphenol supplements could in theory damp the internal stress signals that help tag damaged proteins for turnover. This does **not** mean avoiding all antioxidant foods. It means avoiding megastacks on pulse days. ### CYP3A4 and ribociclib caution Andrographis may have interaction potential with drugs handled through **CYP3A4** and related pathways. That makes extra caution sensible in people on narrow-therapeutic-window medicines or targeted therapies. One practical example is **ribociclib**. In theory, combining andrographis with ribociclib could alter exposure and increase toxicity risk, or alter levels of other CYP3A4-cleared medicines being taken at the same time. This exact herb-drug pair has not been well studied in humans. So any idea of timing andrographis into a ribociclib break is a **theoretical question**, not a recommendation. If considered at all, it needs oncology review and careful monitoring. ### Getting into the cell Andrographolide is a small lipophilic diterpenoid. That means it can cross cell membranes by passive diffusion. Cell and formulation studies suggest that lipid carriers can increase apparent exposure. Liposomes are one example often discussed in this context. That is a formulation argument, not proof that liposomal use improves cancer outcomes. {% hint style="info" %} #### Group member experience One group member described using their standardised Andrographis capsules by emptying 2 capsules into 5 mL of empty liposomes, then splitting that mixture into 2-3 doses throughout the day, holding it briefly under the tongue before swallowing. This is a **personal-use example**, not a recommendation or validated protocol. It should not be treated as evidence that this method improves uptake, efficacy, or outcomes in cancer. {% endhint %} ### Safety Even outside oncology, andrographis is not a trivial herb. Important cautions include: * possible allergic reactions, including serious reactions and anaphylaxis * extra caution in pregnancy and breastfeeding * the need to review interactions with the treating team Stop urgently and seek care if symptoms suggest allergy, such as: * hives or rash * intense itching * lip, face, tongue, or throat swelling * chest tightness * wheeze * difficulty breathing * feeling faint It is wise to make sure the oncologist, GP, and pharmacist all know about any herb or supplement use. ### What this page does not claim This page does **not** claim that andrographis: * has proven human anti-relapse benefit in TP53-mutant cancer * reliably clears all mutant p53 proteins * makes sense in every TP53-mutant setting * should be added casually alongside oncology drugs The evidence here is mechanistic and preclinical. ### Where this fits in the TP53 hub This page only makes sense after: * [Somatic TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53.md) * [TP53 Mutation Types Reference](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53/tp53-mutation-types-reference.md) Those pages help answer whether the tumour actually carries the kind of **stable mutant** protein this idea is trying to target. ### Bottom line The andrographis pulse concept is a **mutation-type-specific clean-up framework**. It is most relevant for **stable mutant p53 protein** states. It is much less relevant when p53 is simply absent or truncated. ### Key references Andrographolide induces degradation of mutant p53 via activation of Hsp70\ Targeting p53 pathways: mechanisms, structures and advances in therapy\ The role of andrographolide as a potential anticancer agent against gastric cancer cell lines: a systematic review\ Proteasome-inhibitor context relevant to the pulse logic\ The proteasome as a druggable target\ Formulation and liposome review relevant to cellular exposure\ Andrographolide review with broader pharmacology context\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/andrographis-and-mutant-p53.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.